Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

The American Association for Cancer Research Annual Meeting 2025 will be held from April 25-30 in Chicago, Illinois, providing a ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Dan Paterson, President and CEO of Verastem, Inc. (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $273 million, recently sold 858 shares of the company's ...